The Cochrane Haematological Malignancies Group (CHMG) is one of 51 Cochrane review groups, which are responsible for the preparation of systematic Cochrane reviews on relevant clinical and health issues.
The Cochrane Haematological Malignancies Group (CHMG) was formed in 2000. The CHMG editorial base is located in Cologne (Germany) and chaired by Prof. Andreas Engert, MD. Our editors are based in Brazil, Germany, Denmark, Israel, Switzerland, UK and USA, our review authors and consumer referees are based all over the world. The CHMG base is affiliated with the University Hospital of Cologne, Department of Internal Medicine I (Haematology and Oncology).
The CHMG is concerned with the evaluation of the diagnosis and  treatment of adults with haematological diseases.The main focus is on leukaemia and lymphoma but the care of those suffering from other haematological diseases like aplastic anaemia is included in the wider scope of the group.  In addition, the group evaluates interventions affecting the haematological cell system like stem cell transplantation and haemotopoetic growth factors. Finally supportive care and the management of haematological diseases is also within the Cochrane Haematological Malignancies Group´s scope.
The work of the CHMG focuses on three main areas.

•  The first is the preparation, publication and maintenance of systematic reviews of the effects of interventions for haematological malignancies. These reviews are published quarterly on The Cochrane Library, and are updated periodically to incorporate new research as it becomes available.
• The second is the development and maintenance of a specialised register of randomised controlled trials relevant to the scope of the group’s work.
• The third is the transfer of generated evidence to clinicians, consumers, policy makers and researchers.

This project has a strong emphasis on evidence-based medicine (EBM) and follows strict Cochrane Collaboration guidelines.

Last update: December 9th 2009 by  NS webmaster(at)chmg.de